Singapore Markets closed
Straits Times Index
3,181.97 -45.13 (-1.40%) S&P 500
3,693.23 -64.76 (-1.72%) Dow
29,590.41 -486.29 (-1.62%) Nasdaq
10,867.93 -198.87 (-1.80%) BTC-USD
19,100.79 +49.98 (+0.26%) CMC Crypto 200
437.32 -7.21 (-1.62%)
Eli Lilly and Company (LLY)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
At close: 04:04PM EDT
Pre-market:
| Previous close | 310.87 |
| Open | 311.87 |
| Bid | 0.00 x 800 |
| Ask | 311.74 x 800 |
| Day's range | 305.12 - 315.18 |
| 52-week range | 220.20 - 335.33 |
| Volume | |
| Avg. volume | 2,549,709 |
| Market cap | 297.94B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 46.63 |
| EPS (TTM) | 6.68 |
| Earnings date | 25 Apr 2022 - 29 Apr 2022 |
| Forward dividend & yield | 3.92 (1.19%) |
| Ex-dividend date | 12 Aug 2022 |
| 1y target est | 304.28 |
- Zacks
Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK
Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.
- Zacks
Strength Seen in Lilly (LLY): Can Its 4.9% Jump Turn into More Strength?
Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- Yahoo Finance Video
Eli Lilly stock upgraded to Buy on forecast for new diabetes drug
UBS analysts upgraded Eli Lilly stock to Buy, stating that the pharma company's Type 2 diabetes medication could become a best-selling drug.
© 2022 Yahoo. All rights reserved.
